Maze Therapeutics Reports $44.7 Million Net Loss in Q2 2026, Increases Operating Expenses

Maze Therapeutics, Inc. reported its financial results for the second quarter of 2026, revealing a net loss of $44.7 million, compared to a net loss of $33.7 million for the same period in 2025. For the first half of 2026, the company recorded a net loss of $68.9 million, slightly higher than the $66.5 million loss reported in the first half of 2025. The increase in losses is attributed to rising operating expenses, which totaled $48.0 million for the second quarter of 2026, up from $36.5 million in the prior year. Research and development expenses rose to $34.9 million from $28.1 million, driven by increased personnel costs and clinical development activities.

Maze Therapeutics did not generate any license revenue in the second quarter of 2026, but reported $20 million in license revenue for the first half of the year, stemming from a milestone payment related to its collaboration with Shionogi & Company. This marks a significant change from the previous year, where no revenue was recorded in the same periods. The company’s total operating expenses for the first half of 2026 reached $94.6 million, compared to $71.9 million in the first half of 2025, reflecting ongoing investments in its clinical programs.

The company’s cash, cash equivalents, and marketable securities stood at $494.9 million as of June 30, 2026, an increase from $360.0 million at the end of 2025. This increase is attributed to the successful completion of an underwritten registered offering in April 2026, which raised approximately $144.6 million, and an initial term loan of $40 million from the Hercules Loan Agreement. The company has also entered into an Open Market Sale Agreement with Jefferies LLC, allowing it to issue up to $200 million in common stock, although no sales have occurred under this agreement to date.

Operationally, Maze Therapeutics is advancing its clinical programs, including MZE829 and MZE782, which target kidney and metabolic diseases. The company has reported positive clinical data for MZE829, with plans to continue enrollment in its Phase 2 trial and initiate a pivotal trial in 2027. The company anticipates that its research and development expenses will continue to rise as it progresses through clinical trials and expands its pipeline. Despite the current financial losses, Maze Therapeutics believes its existing cash reserves will be sufficient to fund operations for at least the next year, although it will require additional capital to support its ongoing development efforts.

Looking ahead, Maze Therapeutics remains focused on advancing its therapeutic candidates and expanding its collaborations. The company acknowledges the need for substantial additional capital to fund its operations and development activities, and it may pursue various financing options, including equity offerings and strategic partnerships. The company’s future financial performance will depend on the successful execution of its clinical trials and the ability to generate revenue from its therapeutic candidates.